Desloratadin-Vertex, 5 mg 10 pcs

Pharmgroup: anti-allergic agent – H1-histamine receptor blocker.

Pharmaceutical effect: Blocker of H1-histamine receptors (long-acting). It is the primary active metabolite of loratadine.
Suppresses the release of histamine and leukotriene C4 from mast cells.

Prevents the development and facilitates the course of allergic reactions.

It has anti-allergic, antipruritic and antiexudative action.

Limits capillary permeability, prevents development of tissue edema, relieves smooth muscle spasm.

It has practically no sedative effect and when taken at a dose of 7.5 mg it does not affect the speed of psychomotor reactions.

In comparative studies of desloratadine and loratadine no qualitative or quantitative differences in toxicity of the 2 drugs in comparable doses (taking into account desloratadine concentration) were found.

Indications

Seasonal and year-round allergic rhinitis, chronic idiopathic urticaria.

Active ingredient

Composition

Panel blue film-coated, round, biconvex; cross-section of the core is white or almost white.

1 tablet: desloratadine 5 mg

Auxiliary substances:

calcium hydrophosphate dihydrate – 53 mg,

cellulose microcrystalline – 27.5 mg,

corn starch – 11 mg,

talc – 2.5 mg,

magnesium stearate – 1 mg.

The composition of the film coating:

dry mixture for film coating (polyvinyl alcohol – 40%, titanium dioxide – 22.1%, macragol 3350 (polyethylene glycol 3350) – 20.2%, talc – 14.8%, indigo carmine dye aluminum varnish – 2.8%, iron oxide yellow (iron oxide) – 0.1%) – 3 mg.

How to take, the dosage

Ingestion. The tablet should be swallowed whole, without chewing, with a small amount of water.

The drug should preferably be taken at the same time of day, regardless of the time of eating.

Adults and adolescents from 12 years: 1 tablet (5 mg) 1 time per day. The duration of therapy depends on the duration of symptoms.

In case of seasonal (intermittent) allergic rhinitis (presence of symptoms of less than 4 days per week or their total duration of less than 4 weeks per year) and urticaria it is necessary to evaluate the course of disease. If symptoms disappear, the drug should be discontinued; if symptoms reappear, the drug should be resumed.

In case of year-round (persistent) allergic rhinitis (presence of symptoms lasting more than 4 days per week or their total duration of more than 4 weeks per year), treatment may continue for the duration of allergen exposure.

The duration of therapy with the drug should be discussed with the physician.

Interaction

In studies with azithromycin, ketoconazole, erythromycin, fluoxetine and cimetidine no interaction with other drugs was found.

Eating has no effect on the effectiveness of the drug.

Desloratadine does not increase the effect of alcohol on the central nervous system.

Special Instructions

There have been no studies on the effectiveness of Desloratadine in rhinitis of infectious etiology.

Influence on the ability to drive and operate vehicles

In taking desloratadine in the recommended dose no adverse effects on driving and operating vehicles have been noted.

In rare cases, however, some patients have experienced drowsiness and dizziness while taking the drug, which may affect their ability to drive and operate machinery.

Contraindications

Hypersensitivity, pregnancy, lactation, childhood (under 1 year), childhood (under 12 years) for tablet forms.

For the syrup (additionally, due to the presence of sucrose and sorbitol): hereditary intolerance to fructose, impaired glucose/galactose absorption or sucrose/isomaltose deficiency.

With caution. Severe renal insufficiency.

Side effects

Rarely: dizziness, somnolence, tachycardia, palpitations, abdominal pain, dyspepsia (including nausea, vomiting, diarrhea), hyperbilirubinemia, increased activity of “liver” enzymes, allergic reactions (skin rash, itching, urticaria, angioedema, anaphylactic shock).

In children under 2 years of age (incidence slightly higher than with placebo): diarrhea, hyperthermia, insomnia.

In 2-11 year olds, the incidence of side effects is comparable to placebo.

In adults and children over 12 years of age (incidence slightly higher than with placebo): increased fatigue, dry mouth, headache; drowsiness (incidence comparable to placebo).

Overdose

Symptoms

Dose of up to 5 times the recommended dose did not result in any symptoms. Daily use of desloratadine in adults and adolescents at a dose up to 20 mg for 14 days was not accompanied by statistically or clinically significant changes in the cardiovascular system. The use of desloratadine at a dose of 45 mg per day (9 times the recommended dose) for 10 days did not cause prolongation of the QT interval and was not accompanied by the appearance of serious side effects.

Treatment

If an accidental ingestion of a large amount of the drug, seek medical attention immediately. Gastric lavage, intake of activated charcoal, and symptomatic therapy, if necessary, is recommended. Desloratadine is not excreted by hemodialysis, the effectiveness of inertial dialysis has not been established.

Pregnancy use

Similarities